Biotech Seeds Global Strategic Business Report 2024: A US$119.2 Billion Market by 2030, growing at a CAGR of 7.3% During 2023-2030
April 23, 2024 03:17 ET
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "Biotech Seeds - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Biotech Seeds estimated...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024 07:13 ET
|
Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Amarna Therapeutics announces appointment of Aurelia Caparrós as new Chief Business Officer
April 19, 2024 04:08 ET
|
Amarna Therapeutics
Leiden, The Netherlands, 19 April 2024 – Amarna Therapeutics, a privately-held biotechnology company developing transformative gene therapies in a range of rare and prevalent diseases, including Type...
Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024
April 18, 2024 16:30 ET
|
Rapid Micro Biosystems, Inc.
LOWELL, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation...
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
April 18, 2024 16:05 ET
|
Lumos Pharma, Inc.
AUSTIN, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at European Society of Clinical Microbiology & Infectious Diseases Global (ESCMID Global) 2024
April 18, 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and
Investigator-Initiated Pre-Clinical Studies at ESCMID Global (Formerly ECCMID)
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and Completion and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
April 18, 2024 06:00 ET
|
Biosplice Therapeutics, Inc.
Presentation of OA-07 Phase 3 Long-Term Results for Lorecivivint and Preliminary Analysis of OA-21 Trial 12-Week Pain Results
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
April 17, 2024 16:05 ET
|
Serina Therapeutics, Inc.
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE...
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
April 17, 2024 08:00 ET
|
Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise
First Wave BioPharma CEO James Sapirstein to Present at the Planet MicroCap Showcase
April 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...